Why can't the immune system control HIV-1? Defining HIV-1-specific CD4 + T cell immunity in order to develop strategies to enhance viral immunity

Immunologic Research

Volumn 35, Issue 1-2, 2006, Pages 89-101

  Ostrowski, Mario A ^a,b   Yu, Qigui ^a   Yue, Feng Yun ^a   Liu, Jun ^a   Jones, Brad ^a   Gu, Xiao X ^a   Loutfy, Mona ^c   Kovacs, Colin M ^c   Halpenny, Roberta ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c Canadian Immunodeficiency Research Collaborative   (Canada)

Author keywords

Apoptosis; CD4+ T cell maturation; Dendritic cells; HIV 1; TNF superfamily

Indexed keywords

B7 ANTIGEN; CD134 ANTIGEN; CD137 LIGAND; CD27 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; HLA DR ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 33749618294     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:35:1:89     Document Type: Review

References (75)

1. Ostrowski MA, Gu JX, Kovacs C, Freedman J, Luscher MA, MacDonald KS. Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-gamma and interleukin-10 responses. J Infect Dis 2001;184:1268-1278.
2. Rosenberg ES, LaRosa L, Flynn T, Robbins G, Walker BD. Characterization of HIV-1-specific T-helper cells in acute and chronic infection. Immunol Lett 1999;66: 89-93.
3. + T cell responses associated with control of viremia. Science 1997;278:1447-1450.
4. Rosenberg ES, Altfeld M, Poon SH, et al: Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-526.
5. Norris PJ, Sumaroka M, Brander C, et al: Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones. J Virol 2001;75:9771-9779.
6. Xiong Y, Luscher MA, Altman JD, et al: Simian immunodeficiency virus (SIV) infection of a rhesus macaque induces SIV-specific CD8(+) T cells with a defect in effector function that is reversible on extended interleukin-2 incubation. J Virol 2001;75:3028-3033.
7. Oxenius A, Zinkernagel RM, Hengartner H. CD4+ T-cell induction and effector functions: a comparison of immunity against soluble antigens and viral infections. Adv Immunol 1998;70:313-367.
8. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395-1402.
9. Reddehase MJ, Koszinowski UH. Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature 1984;312:369-371.
10. + lymphocytes. Science 1999;283:857-860.
11. Klein MR, van Baalen CA, Holwerda AM, et al: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-1372.
12. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999;5:518-525.
13. Harari A, Rizzardi GP, Ellefsen K, et al: Analysis of HIV-1-and CMV-specific memory CD4 T-cell responses during primary and chronic infection. Blood 2002;100: 1381-1387.
14. Wilson JD, Imami N, Watkins A, et al: Loss of CD4+ T cell proliferative ability but not loss of Human Immunodeficiency Virus type 1 specificity equates with progression to disease. J Infect Dis 2000;182:792-798.
15. Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004;103:966-972.
16. Younes SA, Yassine-Diab B, Dumont AR, et al: HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003;198: 1909-1922.
17. McNeil AC, Shupert WL, Iyasere CA, et al: High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci USA 2001; 98:13878-13883.
18. Betts MR, Exley B, Price DA, et al: Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci USA 2005;102: 4512-4517.
19. Douek DC, Brenchley JM, Betts MR, et al: HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002;417:95-98.
20. Yue FY, Kovacs CM, Dimayuga RC, et al: Preferential apoptosis of HIV-1-specific CD4+ T cells. J Immunol 2005;174:2196-2204.
21. Mueller YM, De Rosa SC, Hutton JA, et al: Increased CD95/Fas-induced apoptosis of HIV-specific CD8(+) T cells. Immunity 2001;15:871-882.
22. Budd RC: Activation-induced cell death. Curr Opin Immunol 2001;13:356-362.
23. Adrain C, Martin SJ: The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. Trends Biochem Sci 2001; 26:390-397.
24. Hildeman DA, Mitchell T, Teague TK, et al: Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 1999;10:735-744.
25. Perfettini JL, Roumier T, Castedo M, et al: NF-{kappa}B and p53 are the dominant apoptosis-inducing transcription factors elicited by the HIV-1 envelope. J Exp Med 2004;199:629-640.
26. Genini D, Sheeter D, Rought S, et al: HIV induces lymphocyte apoptosis by a p53-initiated, mitochondrial-mediated mechanism. FASEB J 2001;15:5-6.
27. Lum JJ, Cohen OJ, Nie Z, et al: Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 2003; 111:1547-1554.
28. Valentino KL, Gutierrez M, Sanchez R, Winship MJ, Shapiro DA: First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther 2003;41:441-449.
29. Champagne P, Ogg GS, King AS, et al: Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001;410:106-111.
30. Appay V, Dunbar PR, Callan M, et al: Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002;8:379-385.
31. Draenert R, Tang Y, Verrill C, et al; Vigorous HIV-1 specific CD8 T cell responses in late stage HIV infection. In 10th conference on retroviruses and opportunistic infections. Boston, MA, 2003.
32. Appay V, Nixon DF, Donahoe SM, et al: HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000; 192:63-75.
33. Yue FY, Kovacs CM, Dimayuga RC, Parks P, Ostrowski MA: HIV-1-specific memory CD4(+) T cells are phenotypically less mature than cytomegalovirus- specific memory CD4(+) T cells. J Immunol 2004;172: 2476-2486.
34. Amyes E, Hatton C, Montamat-Sicotte D, et al: Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 2003;198:903-911.
35. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;93:480-483.
36. Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998;393:474-478.
37. Hermans IF, Ritchie DS, Daish A, Yang J, Kehry MR, Ronchese F: Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation. J Immunol 1999;163:77-81.
38. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR: Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-480.
39. Grewal IS, Borrow P, Pamer EG, Oldstone MB, Flavell RA: The CD40-CD154 system in anti-infective host defense. Curr Opin Immunol 1997;9:491-497.
40. Caux C, Massacrier C, Vanbervliet B, et al: Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994;180:1263-1272.
41. Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ, Jr: Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998;161:2094-2098.
42. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-752.
43. Guo Y, Wu Y, Shinde S, Sy MS, Aruffo A, Liu Y: Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. J Exp Med 1996;184:955-961.
44. Koch F, Stanzl U, Jennewein P, et al: High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996;184:741-746.
45. Kennedy MK, Picha KS, Fanslow WC, et al: CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur J Immunol 1996;26:370-378.
46. Yang Y, Wilson JM: CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 1996;273:1862-1864.
47. Ostrowski MA, Justement SJ, Ehler L, et al: The role of CD4(+) T cell help and CD40 ligand in the In vitro expansion of HIV-1-specific memory cytotoxic CD8(+) T cell responses. J Immunol 2000;165:6133-6141.
48. Kuniyoshi JS, Kuniyoshi CJ, Lim AM, et al: Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells. Cell Immunol 1999;193:48-58.
49. Diehl L, den Boer AT, Schoenberger SP, et al: CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments antitumor vaccine efficacy. Nat Med 1999;5:774-779.
50. French RR, Chan HT, Tutt AL, Glennie MJ: CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548-553.
51. Sotomayor EM, Borrello I, Tubb E, et al: Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5:780-787.
52. Bachmann MF, Wong BR, Josien R, Steinman RM, Oxenius A, Choi Y: TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 1999;189:1025-1031.
53. Green EA, Flavell RA: TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation. J Exp Med 1999;189:1017-1020.
54. Wong BR, Josien R, Lee SY, et al: TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-2080.
55. Josien R, Wong BR, Li HL, Steinman RM, Choi Y: TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999;162:2562-2568.
56. Anderson DM, Maraskovsky E, Billingsley WL, et al:A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-179.
57. Josien BR, Li HL, Ingulli E, et al: TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000;191:495-502.
58. Zheng M, Ramsay AJ, Robichaux MB, et al: CD4 T cell-independent DNA vaccination against opportunistic infections. J Clin Invest 2005;115:3536-3544.
59. Yu Q, Gu JX, Kovacs C, Freedman J, Thomas EK, Ostrowski MA: Cooperation of TNF family members CD40 ligand, RANKL, and TNFα in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and -uninfected individuals. Immunol 2003;170:1797-1805.
60. Gramaglia I, Weinberg AD, Lemon M, Croft M: Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998;161: 6510-6517.
61. Ohshima Y, Yang LP, Uchiyama T, et al: OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood 1998;92:3338-3345.
62. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespess G: Expression and function of OX40 ligand on human dendritic cells. J Immunol 1997;159:3838-3848.
63. Chen AI, McAdam AJ, Buhlmann JE, et al: Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 1999;11:689-698.
64. Kopf M, Ruedl C, Schmitz N, et al: OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity 1999;11:699-708.
65. Weinberg AD, Rivera MM, Prell R, et al: Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 2000;164:2160-2169.
66. McHugh RS, Whitters MJ, Piccirillo CA, et al: CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002;16: 311-323.
67. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH: Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285-294.
68. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G: Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001;193:1303-1310.
69. Kinter AL, Hennessey M, Bell A, et al. CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 2004;200:331-343.
70. Yu Q, Yue FY, Gu XX, Schwartz H, Kovacs CM, Ostrowski MA: OX40 ligation of CD4 T cells enhances virus-specific CD8 T cell memory responses independently of IL-2 and CD4 T regulatory cell inhibition. J Immunol 2006;176:2486-2495.
71. Serghides L, Bukczynski J, Wen T, et al: Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL. J Immunol 2005;175:6368-6377.
72. Croft M: Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3:609-620.
73. Watts TH: TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68.
74. Yu Q, Kovacs C, Yue FY, Ostrowski MA: The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell memory responses. J Immunol 2004;172:6047-6056.
75. Stone G, Barzee S, Snarsky V, et al: Multimeric soluble CD40L and GITR L as adjuvants for HIV DNA vaccines. J Virol 2006; 80:in press.